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The effect of carbacyclin, a chemically stable analogue of prostacyclin, on the activity of adenylate cyclase 
in platelet membranes was measured, and compared with the effect of PGEr. When GTP was added in 
concentrations up to 10 PM the activation of adenylate cyclase by carbacyclin was increased, whereas 
higher concentrations of GTP were inhibitory. The addition of a non-hydrolysable analogue of GDP, 
guanosine 5’-[fi-thioldiphosphate (GDP[PS]) resulted in a dose-dependent inhibition of adenylate cyclase 
activation by carbacyclin; this inhibition was relieved by adding increased amounts of GTP. 
Carbacyclin PGE, Adenylate cyclase 
1. INTRODUCTION 
Agents which raise cyclic AMP levels in platelets 
also inhibit platelet aggregation. This is consistent 
with the potent anti-aggregatory action of ‘pros- 
tacyclin (PGI2) a prostaglandin produced by the 
vascular wall which activates adenylate cyclase and 
raises cyclic AMP levels in platelets [1,2]. Com- 
parisons have been carried out on the action of 
PGIz and PGEi on inhibition of platelet aggrega- 
tion, on changes in cyclic AMP levels [1,2] and on 
adenylate cyclase activity [2] and it seems likely 
that PGIz may act on the same receptor as PGEi 
in platelets [3]. 
The experimental use of PGIz is complicated by 
its instability at physiological temperature and pH. 
The development of carbacyclin, a chemically 
stable analogue of prostacyclin has recently led to 
detailed studies on the mechanism of inhibition of 
platelet aggregation, both in vivo and in vitro [4]. 
We have here examined the action of carbacyclin 
on adenylate cyclase activation in platelet mem- 
branes and the role of GTP in this activation. A 
comparison has been made with the action of 
PGEi in this system. 
Abbrevlarioiir GDP[flS], guanosine 5’ -[@-thio]diphos- 
phate 
Platelet membrane GTP GDPM 
2. MATERIALS AND METHODS 
Carbacyclin synthesized as in [5], was kindly 
supplied by Dr B.J.R. Whittle, Wellcome Research 
Laboratories (Langley Court, Beckenham, Kent) 
and PGEi was purchased from Sigma (Poole, 
Dorset). Stock solutions of carbacyclin and of 
PGEi were made up in absolute ethanol and stored 
at - 20°C. When required they were diluted with 
water, added to the adenylate cyclase assay 
cocktail at pH 7.4, and kept in ice until the assay 
was started. GDP[PS] was purchased from Boehr- 
inger (Lewes, East Sussex). 
Membranes were prepared from platelet concen- 
trates as in [6]. As reported, the dose-response 
curves to PGEi for adenylate cyclase activity were 
similar for membranes from platelet concentrates 
and from fresh human platelets. Adenylate cyclase 
activity was assayed as in [7]. The assay contained 
25 mM Tris-HCl buffer (pH 7.4), 0.1 mM ATP, 1 
&i [QY~‘P]ATP, 0.1 mM cyclic AMP, 10 mM 
MgC12, 1 mM dithiothreitol, 5 mM phosphocre- 
atine and 5 units of creatine kinase. Platelet mem- 
branes (20-40 pg protein) were incubated for 10 
min at 37°C in the assay (vol. 0.1 ml). The activity 
of adenylate cyclase was linear for at least 10 min 
under all conditions. 
Protein was determined as in [8]. 
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Fig. 1. Dose-response relation of platelet membranes to 
carbacydin and PGEI. Platelet membranes (22 pg pro- 
tein/assay) were incubated for 10 min at 37’C with GTP 
(10 PM) and with PGEi {o) or carbacyclin (e). 
Adenylate cyclase activity was determined as described 
in section 2. Each point is the mean value from 3 
separate incubations f SE. 
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Fig.2. Effect of increasing concentrations of GTP on 
carba~yclin-stimuIated adenylate cyclase activity. 
Platelet membranes (37 pg protein/assay) were in- 
cubated for 10 min at 37’C with carbacyclin (1 FM) and 
GTP at the concentrations indicated. Basal activity in 
the absence of any additions was 19 f 0.8 pmol. mg 
protein-’ -min-‘. Each point is the mean value from 3 
separate incubations + SE. 
3. RESULTS 
A comparison of the dose-response relation of 
adenylate cyclase in platelet membranes to car- 
bacyclin and to PGEr in the presence of GTP (10 
&Q is shown in fig.1. The dose-response curves 
were very similar, with the curve for carbacyciin 
slightty to the left of that for PGEI. The maximal 
levels of adenylate cyclase activity were the same 
for both carbacyclin and PGEI. Fig.2 shows the ef- 
fect of adding increasing amounts of GTP to 
platelet membranes incubated with carbacyclin (1 
PM). The adenylate cyclase activity increased as 
the concentration of added GTP was increased, 
with maximal activity observed at 10 pM GTP. 
Higher concentrations of GTP (100 PM and mM) 
resulted in some inhibition. 
The effect of GTP on the stimulation of 
adenylate cyclase was further examined using 
GDP[@], a non-hydrolysable analogue of GDP 
which competes with GTP and other guanine 
nucleotides and thus inhibits adenylate cyclase [9J. 
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Fig.3. Effect of GDP[@S] and GTP on carbacyclin- 
stimulated adenylate cyclase activity. Platelet mem- 
branes (20 gg protein/assay) were incubated for 10 min 
at 37% with carbacyciin (0.1 FM) and GTP at the con- 
centrations indicated. GDP[flS] concentrations were: 
(0) none; (0) 10 pM; (0) 0.1 M; (H) 1 mM. Basal ac- 
tivity (no additions) was 81.1 f 5.0 pmol. mg 
protein-’ . min- ‘, Each point is the mean of 3 separate 
incubations YZ SE. 
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Platelet membranes were incubated with car- 
bacyclin (0.1 PM) and the amount of added GTP 
and GDP[PS] systematically varied (fig.3). 
Whereas the addition of 10 FM GDPVS] had little 
effect on adenylate cyclase activity, the addition of 
0.1 mM GDP[flS] and 1 mM GDP[&S] progressive- 
ly inhibited activation. 
4. DISCUSSION 
The dose-response curves of adenylate cyclase 
to carbacyclin and to PGEi were very similar. 
There was also a concentration-dependent effect of 
GTP on the activation of adenylate cyclase by car- 
bacyclin. The role of GTP was further defined us- 
ing GDP[PS], which resulted in a dose-dependent 
inhibition of the carbacyclin activation of 
adenylate cyclase; this was comparable to the in- 
hibitory effect of GDP[PS] on the activation of 
adenylate cyclase by PGEr [6]. 
Carbacyclin has been shown to be rather more 
potent (about 2-fold) than PGEr in the inhibition 
of ADP-induced aggregation of human platelets in 
vitro [4]. However, we here found little difference 
between the dose-response curves of adenylate 
cyclase activated by carbacyclin and PGEr , and the 
maximum stimulation was the same. It appears 
that the differential effects of carbacyclin and 
PGEi on inhibition of platelet aggregation are not 
related to different degrees of activation of 
adenylate cyclase by these compounds. We can 
speculate that there is a further point of regulation 
of cyclic AMP levels, possibly by phospho- 
diesterase, and that in intact platelets different 
levels of cyclic AMP may result from stimulation 
by carbacyclin and PGEi. This effect has been 
described in platelets stimulated by PGI2 and 
PGEr, in which PGI2 had a much higher potency 
(lo-fold) than PGEi in inhibition of platelet ag- 
gregation, and a more marked difference between 
the levels of cyclic AMP produced by PGI2 and 
PGEi, but in which the adenylate cyclase activa- 
tion was the same for both prostaglandins (21. 
We conclude that carbacyclin and PGEi activate 
adenylate cyclase to a similar maximal extent in 
platelet membranes, and that the effect is mediated 
by GTP. 
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